A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma

This is an open-label, nonrandomized, multicenter, Phase 1b study to evaluate the safety and tolerability of talquetamab combination regimens as well as to identify the safe dose(s) of these combination regimens in the treatment of participants with multiple myeloma. Secondary objectives include determining the antitumor activity and pharmacokinetics of each combination regimen. Participants will be enrolled into the available treatment regimen(s), each consisting of different combination agent(s) with talquetamab. The different regimens will include participants across varying stages of multiple myeloma treatment